Neuroendocrine Tumors

CancerConnect neuroendocrine tumor (NET) news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to NET. The unique daily cancer news service evaluates all aspects of NET research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of NET treatment and survivorship.

Neuroendocrine Tumors


Xermelo-new option for controlling symptoms of Carcinoid Syndrome (March 1, 2017)

The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid... Continue Reading

CancerConnect Launches Online Community for Patients with Neuroendocrine Tumors (February 23, 2017)

Sun Valley ID & Austin TX— OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for individuals with neuroendocrine tumors (NET). This community will provide patients... Continue Reading

New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors (January 23, 2017)

A new therapy in development for the treatment of mid-gut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, shows improved outcomes for patients with advanced disease... Continue Reading

Pass It On: It’s National Lung Cancer Awareness Month (November 2, 2016)

There are several types of lung cancer: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and lung carcinoid tumors, with NSCLC and SCLC accounting for about 95% of diagnoses... Continue Reading

What Can Your Gut Tell You About Cancer? (October 16, 2015)

Learn to identify and manage gastrointestinal issues to maintain overall health. By Mia James At the very least, gastro­intestinal (GI) symp­toms are bother­some and sometimes embarrassing. No one feels... Continue Reading

All of Us at CancerConnect Would Like to Wish You a Safe and Happy New Year (December 31, 2014)

Facing the holidays after a diagnosis of cancer can be stressful. Join us on CancerConnect’s online support group where you can connect with others, share your holiday coping tips, and find support.... Continue Reading

Afinitor Approved for Pancreatic Neuroendocrine Tumors (May 10, 2011)

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon... Continue Reading

Afinitor Delays Progression of Advanced Pancreatic Neuroendocrine Tumors (July 8, 2010)

In a recent Phase III trial, the targeted therapy Afinitor® (everolimus) more than doubled progression-free survival time among patients with advanced pancreatic neuroendocrine tumors (NET). Results of... Continue Reading

Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (March 30, 2010)

Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo... Continue Reading

Afinitor and Temodar Active against Pancreatic Neuroendocrine Tumors (February 24, 2010)

The combination of Afinitor® (everolimus) and Temodar® (temozolomide) appears to be active against advanced pancreatic neuroendocrine tumors. The details of this Phase I/II study were presented at the... Continue Reading

Sandostatin LAR Depot Active Against Advanced Neuroendocrine Tumors of the Midgut (October 2, 2009)

Among patients with advanced neuroendocrine tumors of the midgut, treatment with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) appears to significantly delay cancer progression.... Continue Reading

Eat, Drink, and Be Wary? (March 11, 2009)

The unclear relationship between diet and cancer By Emily A. Kuhl, PhD While most of us are stocking our kitchens with milk, bread, and the usual pantry staples, the two items that Carol Martin of Alexandria,... Continue Reading

LX1032 Granted Fast-track Status for Carcinoid Syndrome (June 19, 2008)

Lexicon Pharmaceutical’s investigative agent LX1032 has been granted fast-track status by the United States Food and Drug Administration (FDA). LX1032 is an inhibitor of tryptophan hydroxylase (HTP),... Continue Reading

Combination Chemotherapy May Improve Outcome of Advanced Carcinoid Tumor (August 10, 2005)

Combination Chemotherapy May Improve Outcome of Advanced Carcinoid Tumor The Journal of Clinical Oncology has recently published an article that finds that a combination of the chemotherapy drugs 5-fluorouaracil... Continue Reading

New Targeted Therapy Shows Promise for the Treatment of Prostate Cancer (July 20, 2005)

New Targeted Therapy Shows Promise for the Treatment of Prostate Cancer The Journal of Clinical Oncology has recently published an article indicating that a new prostate cancer therapy has shown promise... Continue Reading

Proteomic Analysis May Improve Diagnostic Precision in NSCLC (August 21, 2003)

Proteomic Analysis May Improve Diagnostic Precision in NSCLC According to a recent article published in The Lancet, proteomic patterns may provide improved diagnostic precision in patients with... Continue Reading

Gastrointestinal Carcinoid Tumor: Lanreotide Is a Convenient, Effective Drug for Relieving Symptoms of Flushing and Diarrhea (February 12, 2002)

Gastrointestinal Carcinoid Tumor: Lanreotide Is a Convenient, Effective Drug for Relieving Symptoms of Flushing and Diarrhea Gastrointestinal carcinoid tumors are cancers that can cause flushing,... Continue Reading

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS